← Back to guidelines
Psychiatry48 papers

Hallucinogen dependence in remission

Last edited: 4/10/2026

Overview

Hallucinogen dependence in remission refers to a state where an individual previously diagnosed with hallucinogen use disorder no longer meets the criteria for active dependence but may still experience cravings or be at risk for relapse. The management of this condition focuses on preventing relapse and supporting sustained abstinence.

Management

  • Psilocybin-assisted therapy (PAT) has shown promising effects in treating depressive symptoms, with overall large treatment effects in both short-term and long-term follow-up 1.
  • However, no significant association was found between the number of therapy hours and treatment outcomes in PAT for depression 1.
  • All included studies in one meta-analysis provided some degree of therapy, ranging from 4.5 to 18 hours 1.
  • Key Recommendations

  • Psilocybin-assisted therapy demonstrates significant treatment effects for depressive symptoms, though the specific contribution of therapy hours to outcomes remains unclear 1. (Evidence: Moderate)
  • Further research with greater methodological rigor and standardized reporting of therapeutic components is needed to clarify the role of therapy in psychedelic-assisted interventions 1. (Evidence: Expert opinion)
  • References

    1 Hultgren J, Hafsteinsson MH, Brulin JG. A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy. General hospital psychiatry 2025. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG